...
首页> 外文期刊>Immunology and Cell Biology >Genetic co-transfer of CCR7 ligands enhances immunity and prolongs survival against virulent challenge of pseudorabies virus.
【24h】

Genetic co-transfer of CCR7 ligands enhances immunity and prolongs survival against virulent challenge of pseudorabies virus.

机译:CCR7配体的遗传共转移可增强免疫力,并延长抵抗伪狂犬病病毒攻击的生存期。

获取原文
获取原文并翻译 | 示例

摘要

The CC chemokine receptor 7 (CCR7) and cognate CCR7 ligands, CCL19 and CCL21, help establish microenvironments in lymphoid tissue that can facilitate encounters between naive T cells and mature dendritic cells (DCs). This study was conducted to determine if CCR7 ligands can augment the immunogenicity of a DNA vaccine that expresses glycoprotein B (gB) of the pseudorabies virus (PrV). The genetic co-transfer of CCR7 ligands along with a PrV DNA vaccine increased the levels of serum PrV-specific immunoglobulin (Ig) G by 2- to 2.5-fold. In addition, the level of PrV-specific IgG2a isotype was significantly enhanced by co-injection of CCR7 ligand DNA, which indicates that CCR7 ligand biases the humoral immunity toward the Th1-type pattern. The co-injection of CCR7 ligand DNA consistently enhanced the level of Th1-type cytokines (IL-2 and IFN-gamma) produced by stimulated immune cells when compared with a group that was vaccinated with the PrV DNA vaccine. Also, the genetic co-transfer of CCR7 ligand DNAs with PrV DNA vaccine provided prolonged survival against a virulent challenge by PrV. Moreover, the co-administration of CCR7 ligand DNA increased the number of mature DCs into the secondary lymphoid tissues, which appeared to enhance the proliferation of PrV-immune CD4(+) T cells. Taken together, these findings indicate that CCR7 ligands are an attractive adjuvant for a PrV DNA vaccine that can offer protective immunity against the PrV.
机译:CC趋化因子受体7(CCR7)和相关的CCR7配体CCL19和CCL21有助于在淋巴组织中建立微环境,从而促进幼稚T细胞和成熟树突状细胞(DC)的相遇。进行这项研究以确定CCR7配体是否可以增强表达伪狂犬病病毒(PrV)糖蛋白B(gB)的DNA疫苗的免疫原性。 CCR7配体的遗传共转移以及PrV DNA疫苗使血清PrV特异性免疫球蛋白(Ig)G的水平增加了2到2.5倍。另外,通过共同注射CCR7配体DNA可以显着提高PrV特异性IgG2a同种型的水平,这表明CCR7配体使体液免疫偏向了Th1型模式。与接种PrV DNA疫苗的组相比,CCR7配体DNA的共同注射始终提高了受刺激的免疫细胞产生的Th1型细胞因子(IL-2和IFN-γ)的水平。而且,CCR7配体DNA与PrV DNA疫苗的基因共转移可延长抵抗PrV毒性攻击的存活时间。此外,CCR7配体DNA的共同给药增加了进入次级淋巴组织的成熟DC的数量,这似乎增强了PrV免疫CD4(+)T细胞的增殖。综上所述,这些发现表明CCR7配体是可提供针对PrV的保护性免疫力的PrV DNA疫苗的有吸引力的佐剂。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号